| A240 |
Imsidolimab Biosimilar（Anti-IL-1RL2 / IL-36R Reference Antibody）
Featured
|
Imsidolimab (ANB 019) is a high-affinity, humanized monoclonal antibody of anti-IL-36R. Imsidolimab antagonizes IL-36 cytokine signal transduction. Imsidolimab has potential application in generalized pustular psoriasis (GPP) and other inflammatory skin diseases. |
.png)
|
| A241 |
Fletikumab Biosimilar（Anti-IL-20 Reference Antibody）
Featured
|
Fletikumab (NNC0109-0012) is a monoclonal antibody targeting to IL-20. Fletikumab can be used for inflammation research, such as rheumatoid arthritis. |
.png)
|
| A242 |
Cheng Kung U. patent anti-IL-20 Biosimilar（Anti-IL-20 Reference Antibody）
Featured
|
|
|
| A243 |
Cheng Kung U. patent anti-IL-20R1 Biosimilar（Anti-IL-20Ra Reference Antibody）
Featured
|
|
|
| A244 |
Avizakimab Biosimilar（Anti-IL-21 Reference Antibody）
Featured
|
Avizakimab (BOS161721) is a humanized IgG1 monoclonal antibody that targets interleukin-21. |
.png)
|
| A245 |
Lilly patent anti-IL-21 Biosimilar（Anti-IL-21 Reference Antibody）
Featured
|
|
|
| A246 |
Fezakinumab Biosimilar（Anti-IL-22 Reference Antibody）
Featured
|
Fezakinumab is an interleukin-22 (IL-22) monoclonal antibody. Fezakinumab can be used for the research of inflammatory disease, such as psoriasis and rheumatoid arthritis. |
.png)
|
| A247 |
ARGX-112 Biosimilar（Anti-IL-22Ra Reference Antibody）
Featured
|
|
|
| A248 |
Guselkumab Biosimilar（Anti-IL-23 Reference Antibody）
Featured
|
Guselkumab is a recombinant human IgG1 monoclonal antibody against the IL-23p19 subunit. Guselkumab binds to human and cynomolgus monkey IL-23 with Kd values of 3.3 and 1.9 pmol/L, respectively. Guselkumab inhibits production of cytokines lying downstream of the IL-23 signaling pathway and can be used for psoriatic arthritis research. |
.png)
|
| A249 |
Mirikizumab Biosimilar（Anti-IL-23 Reference Antibody）
Featured
|
Mirikizumab (LY3074828) is a humanized IgG4 monoclonal antibody that targets the p19 subunit of interleukin 23 (IL-23). Mirikizumab binds to human and monkey IL-23 with high affinity, with Kd values of 21 pM and 55 pM, respectively. By inhibiting the binding of IL-23 to IL-23R, Mirikizumab modulates the immune response and holds potential for research in ulcerative colitis and Crohn's disease. |
.png)
|
| A250 |
LY2525623 Biosimilar（Anti-IL-23 Reference Antibody）
Featured
|
|
|
| A251 |
Brazikumab Biosimilar（Anti-IL-23 Reference Antibody）
Featured
|
Brazikumab (AMG 139) is a human IgG2 monoclonal antibody, selectively binds the p19 subunit of IL-23, with a KD of 0.138 nM for human IL-23. Brazikumab can be used for the research of Crohn's disease. |
.png)
|
| A252 |
Tildrakizumab Biosimilar（Anti-IL-23a Reference Antibody）
Featured
|
Tildrakizumab (SCH 900222) is a humanized anti-IL-23 (p19 subunit) monoclonal antibody. IL-23 is a critical cytokine to maintain the Th17 cell phenotype. Tildrakizumab has high-affinity for single-chain IL-23 (Kd: 136 pM). Tildrakizumab is effective against moderate to severe plaque psoriasis. |
.png)
|
| A128 |
Risankizumab Biosimilar（Anti-IL-23a Reference Antibody）
Featured
|
Risankizumab (BI 655066) is a humanised IgG monoclonal antibody, targeting IL-23 p19 subunit (Kd <10 pM) and inhibiting IL-17 production induced by human IL-23 in mouse splenocytes (IC50 = 2 pM). Risankizumab can be used to research immunological and inflammatory disorders such as psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis and erythrodermic psoriasis. |
|
| A253 |
Centocor patent anti-IL-25 Biosimilar（Anti-IL-25 Reference Antibody）
Featured
|
|
|
| A254 |
Dacliximab Biosimilar（Anti-IL-2Ra / CD25 Reference Antibody）
Featured
|
Daclizumab (Zenapax) is a humanized, monoclonal antibody that blocks CD25 (α-subunit of the high-affinity interleukin-2 receptor (IL-2R-HA)). Daclizumab (Zenapax) reversibly binds to CD25and prevents the interaction of IL-2 with the IL-2R-HA. Daclizumab (Zenapax) can be used for multiple sclerosis research. |
.png)
|
| A255 |
Camidanlumab Biosimilar（Anti-IL-2Ra / CD25 Reference Antibody）
Featured
|
Camidanlumab (HuMax-TAC) is a CD25 monoclonal antibody. Camidanlumab targets the cell-surface antigen CD25, which is over-expressed on a variety of hematological tumors and shows limited expression on normal tissues. Camidanlumab can be used for synthesis of antibody agent conjugates (ADCs) to research several diseases including lymphoma and leukemia. |
.png)
|
| A256 |
Singapore ASTR patent anti-IL-2R beta / IL-2R gamma Biosimilar（Anti-IL-2Rb / CD122 Reference Antibody）
Featured
|
|
|
| A257 |
Nemolizumab Biosimilar（Anti-IL-31Ra Reference Antibody）
Featured
|
Nemolizumab (CIM331) is a humanized antihuman interleukin-31 receptor A monoclonal antibody that inhibits the binding of interleukin-31 (IL-31) to its receptor and subsequent signal transduction. Nemolizumab can used be in research of atopic dermatitis (AD). |
.png)
|
| A258 |
Itepekimab Biosimilar（Anti-IL-33 Reference Antibody）
Featured
|
Itepekimab (REGN-3500) is an IgG4 monoclonal antibody against IL-33. Itepekimab reduced airway inflammation and related tissue damage in preliminary clinical studies. Itepekimab has potential effects in asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis (AD). |
|
| A259 |
Tozorakimab Biosimilar（Anti-IL-33 Reference Antibody）
Featured
|
Tozorakimab (MEDI-3506) is a human immunoglobulin G1 monoclonal antibody targeting interleukin-33. Tozorakimab reduces inflammation and epithelial dysfunction. Tozorakimab can be used to research chronic obstructive pulmonary disease. |
|
| A260 |
Torudokimab Biosimilar（Anti-IL-33 Reference Antibody）
Featured
|
|
|
| A261 |
Etokimab Biosimilar（Anti-IL-33 Reference Antibody）
Featured
|
Etokimab (Antibody ANB 020) is a humanized monoclonal antibody that targets IL-33. Etokimab can be used for the research of atopic dermatitis. |
|
| A262 |
Talacotuzumab Biosimilar（Anti-IL-3Ra / CD123 Reference Antibody）
Featured
|
Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has KDs of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V, respectively. Talacotuzumab inhibits IL-3 binding to CD123, antagonizing IL-3 signaling in target cells. Talacotuzumab has mutated the Fc region to increase affinity for CD16 (FcγRIIIa), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab is highly effective in vivo reducing leukemic cell growth in acute myeloid leukemia (AML) xenograft mouse models. |
|
| A263 |
SNG-CD123A Biosimilar(Anti-IL-3Ra / CD123 Reference Antibody)
Featured
|
|
|
| A264 |
MEDI2045 Biosimilar(Anti-IL-4Ra / CD124 Reference Antibody)
Featured
|
|
|
| A265 |
Depemokimab Biosimilar(Anti-IL-5 Reference Antibody)
Featured
|
Depemokimab (GSK-3511294) is a long-acting anti-IL-15 monoclonal antibody. Depemokimab can be used for research of asthma. |
|
| A266 |
Abgenix anti-IL-5 Biosimilar(Anti-IL-5 Reference Antibody)
Featured
|
|
|
| A267 |
Sirukumab Biosimilar(Anti-IL-6 / IFNb2 Reference Antibody)
Featured
|
Sirukumab (CNTO-136) is a humanized monoclonal anti-IL6 (Interleukin Related) IgG1κ antibody. Sirukumab binds to IL6, preventing IL6-mediated signal transduction and activation of transcriptional activators, thereby blocking the downstream biological effects of IL6. Sirukumab can be used in the study of active lupus nephritis and rheumatoid arthritis. |
|
| A268 |
Elsilimomab Biosimilar(Anti-IL-6 / IFNb2 Reference Antibody)
Featured
|
Elsilimomab (B-E8) is a IgG1 monoclonal antibody against interleukin-6 (IL-6), with a KD of 22 pM and an IC50 of 1.4 nM. Elsilimomab can be used for the research of multiple myeloma, renal cell carcinoma, and rheumatoid arthritis (RA). |
|
